In the past decade, CT has established itself as a workhorse in providing anatomical landmarks for molecular imaging. Pairing of the technology with traditional nuclear medicine modalities such as SPECT and PET has propelled the growth of molecular imaging beyond the boundaries of academic research into the mainstream of clinical care.

The National Cancer Institute and researchers around the globe are exploring and developing an array of new biomarkers that could edge molecular imaging toward routine clinical practice and help deliver on the promise of personalized medicine.

Just five years ago, the thought of cardiac cross-sectional imaging turned immediately toward the potential of MRI for evaluation of the heart. Equipment manufacturers provided new MRI scanners with fast gradients for this purpose and developed new pulse sequences. Advanced 3D workstations provided new software for analysis of cardiac function, and

Michael Milbourne, MD, of New Life Cardiovascular in Wyndmoor, Pa., anuclear cardiologist in academic and private practice, is committed tooffering his patients outstanding, informed and proactive clinicalcare. In the last year, SPECT/CT has become an essential diagnostictool in Milbourne’s practice. 

PET/CTa technology whose potential is now being appreciated, but has yet to be fully realizedhas proven successful in the accurate staging and monitoring of oncology patient therapy for a variety of cancers. SPECT/CT, while relatively new, is beginning to make its mark in areas such as oncology, cardiology, neurology imaging. 

Diagnosing heart disease in women—the No. 1 cause of death of womenacross the globe—is sometimes difficult, but molecular PET and SPECTimaging is beginning to contribute to resolving this problem.

13N-ammonia, an established imaging probe for measuringmyocardial perfusion, has now been made available for use in thecommunity. This has thus far been difficult because of the shorthalf-life of 13N-ammonia of about 10 minutes. But even that time factor has been worked out.

 PET/CT and SPECT/CT are helping to detect and diagnose coronary artery disease in women earlier and better. Previously under-diagnosed or misdiagnosed altogether particularly in women, new exams are effectively assessing myocardial perfusion, offering an alternative to nuclear stress tests that often lead to false positive results in women. Fewer attenuation artifacts also mean sharper images.